Nakodai Mara'dia Abanua Kaiyang Toilopi: Spirit Nilai Budaya Maritim dan Identitas Orang Mandar

Artikel ini membahas orang Mandar sebagai suku bangsa maritim yang tidak diragukan eksistensinya. Sebagai pemangku kebudayaan maritim dan religius yang taat, tidak dapat dimungkiri keandalan manusia Mandar dalam berbagai arena kehidupan dan selalu memiliki ciri khas yang dapat bernilai positif. Metode penelitian deskriptif kualitatif dengan melakukan penelitian di Polewali Mandar dan Majene. Adapun teknik pengumpulan data dengan studi pustaka, pengamatan dan wawancara. Hasil penelitian menunjukkan bahwa sebagai suku bangsa maritim, sangatlah urgen untuk melakukan penggalian nilai-nilai luhur masyarakat Mandar yang selalu menonjol dalam berbagai arena sosial, ekonomi dan politik. Orang Mandar memiliki nilai budaya yang khas yang selalu unggul dalam berbagai arena sosial, politik, hukum dan ekonomi. Bangsa Indonesia memiliki Baharuddin Lopa dan Basri Hasanuddin yang mewarnai peradaban Indonesia. Nilai-nilai luhur takkalai disombalang dotai lele rapu dadi na tuali di lolangan.” Orang Mandar menjunjung tinggi halhal yang baik, benar dan mulia. Nilai ini mengisyaratkan bahwa mereka bercita-cita menjadikan wilayahnya “Mandar masagena na mala bi” yang berarti “wilayah Mandar yang terpandang dan mulia.” Nilai-nilai inilah menjadi penopang kebudayaan Mandar sehingga melahirkan manusia Mandar yang selalu unggul dalam berbagai arena sebagai identitas suku bangsa maritim

Superconducting state in the non-centrosymmetric Mg_{9.3}Ir_{19}B_{16.7} and Mg_{10.5}Ir_{19}B_{17.1} revealed by NMR

We report ^{11}B NMR measurements in non-centrosymmetric superconductors Mg_{9.3}Ir_{19}B_{16.7} (T_c=5.8 K) and Mg_{10.5}Ir_{19}B_{17.1} (T_c=4.8 K). The spin lattice relaxation rate and the Knight shift indicate that the Cooper pairs are predominantly in the spin-singlet state with an isotropic gap. However, Mg_{10.5}Ir_{19}B_{17.1} is found to have more defects and the spin susceptibility remains finite even in the zero-temperature limit. We interpret this result as that the defects enhance the spin-orbit coupling and bring about more spin-triplet component.Comment: for a proper, high-resolution Fig.5, contact the corresponding autho

Variational Monte Carlo Study of the Kondo Necklace Model with Geometrical Frustration

We investigate the ground state of the Kondo necklace model on geometrically-frustrated lattices by the variational Monte Carlo simulation. To explore the possibility of a partially-ordered phase, we employ an extension of the Yosida-type wave function as a variational state, which can describe a coexistence of spin-singlet formation due to the Kondo coupling and magnetic ordering by the Ruderman-Kittel-Kasuya-Yosida interaction. We show the benchmark of the numerical simulation to demonstrate the high precision brought by the optimization of a large number of variational parameters. We discuss the ground-state phase diagram for the model on the kagome lattice in comparison with that for the triangular-lattice case.Comment: 3 pages, proceedings for ICHE201

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck : Evidence, Advantages, and Future Directions

The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression (EXTREME), resulted in the first regimen to yield significantly improved survival outcomes in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in over 30 years. Currently, the EXTREME regimen is a guideline-recommended treatment in the first-line R/M setting, and, therefore, it is used as a control arm in all new first-line, phase 3 immunotherapy trials. More recently, new checkpoint inhibitor approaches have emerged and are changing the treatment landscape for PD-L1\u2013positive patients with R/M SCCHN. Additionally, alternative chemotherapy backbones in R/M SCCHN are continually investigated. Replacing 5-FU with a taxane in the EXTREME regimen seeks to take advantage of the potential immunogenic and proapoptotic synergy between cetuximab and docetaxel or paclitaxel. These cetuximab-, platinum-, and taxane-based treatments have demonstrated promising survival results and cytoreductive properties in single-arm studies. Thus, these combination treatments may be of importance to patients with high tumor burden and dangerous site involvements (e.g., causing bleeding, suffocation, dysphagia, or ulceration), in whom symptom relief is a key treatment goal. TPExtreme is the first large, randomized trial comparing a cetuximab, platinum, and taxane combination regimen with EXTREME. Currently, the substitution of 5-FU with a taxane is a feasible and clinically beneficial option for patients with contraindications to 5-FU. The TPEx regimen appears to be a new option in first-line R/M SCCHN, with a shorter time on CT and significantly lower toxicity than the EXTREME regimen. For patients with R/M disease in whom further cisplatin- or carboplatin-based treatment is unsuitable, or whose disease has already progressed on first-line R/M therapy, treatment options such as cetuximab plus a taxane, which capitalize on the combinative ability of the 2 agents, can be considered. Notably, it is as of yet unknown what second-line treatments may be suitable to follow a checkpoint inhibitor-based first-line therapy

Studies on Functional Bacteria of Indonesian Tropical Forest Plants for Biorehabilitation of Degraded Lands

Forest degradations have left vast amount of damaged and abandoned lands in Indonesia. In this paper, we present our approaches in rehabilitation of adverse soils using functional bacteria isolated from plant species of Indonesian tropical rain forests. For these purposes, we collected bacteria from various bio-geo-climatically different forests and conducted bioassays to test these bacterial abilities in improving plant growth. Repeated seedling-based studies on Shorea spp., Alstonia scholaris, Acacia crassicarpa, and Agathis lorantifolia have revealed that many bacteria were able to promote plant growth at early stage in the nursery. Various plant responses towards inoculations suggested that although forest soils maintain highly diverse and potent bacteria, it is necessary to select appropriate approaches to obtain optimum benefits from these plant-bacteria interactions. Our ideas and futures studies for further management of these plant- bacteria interactions for biorehabilitation are also discussed

Layer-specific morphological and molecular differences in neocortical astrocytes and their dependence on neuronal layers

Non-pial neocortical astrocytes have historically been thought to comprise largely a nondiverse population of protoplasmic astrocytes. Here we show that astrocytes of the mouse somatosensory cortex manifest layer-specific morphological and molecular differences. Two- and three-dimensional observations revealed that astrocytes in the different layers possess distinct morphologies as reflected by differences in cell orientation, territorial volume, and arborization. The extent of ensheathment of synaptic clefts by astrocytes in layer II/III was greater than that by those in layer VI. Moreover, differences in gene expression were observed between upper-layer and deep-layer astrocytes. Importantly, layer-specific differences in astrocyte properties were abrogated in reeler and Dab1 conditional knockout mice, in which neuronal layers are disturbed, suggesting that neuronal layers are a prerequisite for the observed morphological and molecular differences of neocortical astrocytes. This study thus demonstrates the existence of layer-specific interactions between neurons and astrocytes, which may underlie their layer-specific functions

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Background: Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SCCHN). We assessed the efficacy and safety of panitumumab combined with cisplatin and fluorouracil as first-line treatment for these patients. Methods: This open-label phase 3 randomised trial was done at 126 sites in 26 countries. Eligible patients were aged at least 18 years; had histologically or cytologically confi rmed SCCHN; had distant metastatic or locoregionally recurrent disease, or both, that was deemed to be incurable by surgery or radiotherapy; had an Eastern Cooperative Oncology Group performance status of 1 or less; and had adequate haematological, renal, hepatic, and cardiac function. Patients were randomly assigned according to a computer-generated randomisation sequence (1:1; stratifi ed by previous treatment, primary tumour site, and performance status) to one of two groups. Patients in both groups received up to six 3-week cycles of intravenous cisplatin (100 mg/m(2) on day 1 of each cycle) and fl uorouracil (1000 mg/m(2) on days 1-4 of each cycle); those in the experimental group also received intravenous panitumumab (9 mg/kg on day 1 of each cycle). Patients in the experimental group could choose to continue maintenance panitumumab every 3 weeks. The primary endpoint was overall survival and was analysed by intention to treat. In a prospectively defi ned retrospective analysis, we assessed tumour human papillomavirus (HPV) status as a potential predictive biomarker of outcomes with a validated p16-INK4A (henceforth, p16) immunohistochemical assay. Patients and investigators were aware of group assignment; study statisticians were masked until primary analysis; and the central laboratory assessing p16 status was masked to identifi cation of patients and treatment. This trial is registered with ClinicalTrials. gov, number NCT00460265. Findings: Between May 15, 2007, and March 10, 2009, we randomly assigned 657 patients: 327 to the panitumumab group and 330 to the control group. Median overall survival was 11.1 months (95% CI 9.8-12.2) in the panitumumab group and 9.0 months (8.1-11.2) in the control group (hazard ratio [HR] 0.873, 95% CI 0.729-1.046; p = 0.1403). Median progression-free survival was 5.8 months (95% CI 5.6-6.6) in the panitumumab group and 4.6 months (4.1-5.4) in the control group (HR 0.780, 95% CI 0.659-0.922; p = 0.0036). Several grade 3 or 4 adverse events were more frequent in the panitumumab group than in the control group: skin or eye toxicity (62 [19%] of 325 included in safety analyses vs six [2%] of 325), diarrhoea (15 [5%] vs four [1%]), hypomagnesaemia (40 [12%] vs 12 [4%]), hypokalaemia (33 [10%] vs 23 [7%]), and dehydration (16 [5%] vs seven [2%]). Treatment-related deaths occurred in 14 patients (4%) in the panitumumab group and eight (2%) in the control group. Five (2%) of the fatal adverse events in the panitumumab group were attributed to the experimental agent. We had appropriate samples to assess p16 status for 443 (67%) patients, of whom 99 (22%) were p16 positive. Median overall survival in patients with p16-negative tumours was longer in the panitumumab group than in the control group (11.7 months [95% CI 9.7-13.7] vs 8.6 months [6.9-11.1]; HR 0.73 [95% CI 0.58-0.93]; p = 0.0115), but this difference was not shown for p16-positive patients (11.0 months [7.3-12.9] vs 12.6 months [7.7-17.4]; 1.00 [0.62-1.61]; p = 0.998). In the control group, p16-positive patients had numerically, but not statistically, longer overall survival than did p16-negative patients (HR 0.70 [95% CI 0.47-1.04]). Interpretation: Although the addition of panitumumab to chemotherapy did not improve overall survival in an unselected population of patients with recurrent or metastatic SCCHN, it improved progression-free survival and had an acceptable toxicity profile. p16 status could be a prognostic and predictive marker in patients treated with panitumumab and chemotherapy. Prospective assessment will be necessary to validate our biomarker findings